A cluster of women-led healthcare firms is developing noninvasive, multiomics tests for earlier endometriosis diagnosis using menstrual fluid. The companies are building assays that focus on menstrual-blood analytes and are converging toward similar commercialization timelines, with endometriosis affecting roughly 10% of reproductive-age people. The current diagnostic standard is often surgical lesion removal and pathology, with reports that 40% to 50% of lesions test negative. That contributes to an average seven-year wait for diagnosis, while existing treatments manage symptoms rather than cure the underlying condition. Endometrix’s CEO Yana Aznavour attributed the uptick to a “convergence of forces,” including increased patient advocacy and demand for answers. Diamens, an Austrian firm, is developing an RNA-seq-based test and said it aims to launch in Europe next year after closing a “six-figure” financing round. For biotech, the shift is notable: these programs aim to convert multiomics and menstrual-sample biobanking into clinically actionable diagnostics that can reduce reliance on invasive procedures.